12 February 2025 - NKGen Biotech today announced that the US FDA has granted fast track designation for the investigation of troculeucel, ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer’s disease.

NKGen is currently enrolling patients in its Phase 2a trial for moderate AD and expects to share updated clinical data by the end of 2025.

Read NKGen Biotech press release